Objectives Report complications encountered by members of a collaborative group performing MTA in patients with focal liver cancer Shimada et al () Case series N = 29 Inclusion and exclusion criteria not MTA Outcomes Old study reported Japan Level IV Male/female: 21/8 Open (n = 23) or Complications Objectives percutaneous (n = 6) Quality: Mean age not reported Statistical analysis approach, using Microtase for whole group; Describe complications moderate None undertaken (Nippon Shoji, Osaka, 62.7 y encountered using MTA Follow-up Japan) 11–55 months 2450 MHz, 100 W for open and 60 W for percutaneous Ablation time 60 s Ierardi et al () Case series N = 25 Inclusion MTA: Outcomes - Absence of or stable extrahepatic Percutaneous MTA Technical success, disease-free Italy Level IV Metastases from: disease (Evident, Covidien, USA) survival, safety and efficacy Quality: moderate CRC: 21 Inoperable lesions 915 MHz, 45 W Statistical analyses Breast: 2 Tumour size >3 cm Antenna 14.5-gauge Kaplan–Meyer method for Pharynx: 1 (Evident MW Ablation evaluation of survival Lesions located near vessels with Oesophagus: 2 Percutaneous Antenna), diameter >3 mm Duration of follow-up Retroperitoneal continuously with Exclusion Mean 12.04 months (range 3–36 leiomyosarcoma: 1 saline solution to avoid months) Surgically treatable lesions or Gallbladder: 2 possible thermal damage amenable to RFA (not described) Renal: 1 All lesions treated with 2 or Objectives Pancreatic: 1 3 antennae simultaneously To evaluate the technical success, Male/female: 17/8 Total ablation time 10 min effectiveness and safety of MTA to Mean age (range): overcome the limits of RFA 65.9 (49–83) y Liang et al () Case series N = 74 Inclusion MTA Outcomes 16 patients eligible for resection elected to have China Level IV Metastases from: None specified Ultrasound-Guided Survival, complications MTA Microwave Coagulator-I Quality: poor CRC: 28 Exclusion Statistical analyses
Objectives Report complications encountered by members of a collaborative group performing MTA in patients with focal liver cancer Shimada et al () Japan Case series Level IV Quality: moderate N = 29 Male/female: 21/8 Mean age not reported for whole group; y Inclusion and exclusion criteria not reported Objectives Describe complications encountered using MTA MTA Open (n = 23) or percutaneous (n = 6) approach, using Microtase (Nippon Shoji, Osaka, Japan) 2450 MHz, 100 W for open and 60 W for percutaneous Ablation time 60 s Outcomes Complications Statistical analysis None undertaken Follow-up 11–55 months Old study Ierardi et al () Italy Case series Level IV Quality: moderate N = 25 Metastases from: CRC: 21 Breast: 2 Pharynx: 1 Oesophagus: 2 Retroperitoneal leiomyosarcoma: 1 Gallbladder: 2 Renal: 1 Pancreatic: 1 Male/female: 17/8 Mean age (range): 65.9 (49–83) y Inclusion Absence of or stable extrahepatic disease Inoperable lesions Tumour size >3 cm Lesions located near vessels with diameter >3 mm Exclusion Surgically treatable lesions or amenable to RFA (not described) Objectives To evaluate the technical success, effectiveness and safety of MTA to overcome the limits of RFA MTA: Percutaneous MTA (Evident, Covidien, USA) 915 MHz, 45 W Antenna 14.5-gauge (Evident MW Ablation Percutaneous Antenna), continuously with saline solution to avoid possible thermal damage All lesions treated with 2 or 3 antennae simultaneously Total ablation time 10 min Outcomes Technical success, disease-free survival, safety and efficacy Statistical analyses Kaplan–Meyer method for evaluation of survival Duration of follow-up Mean 12.04 months (range 3–36 months) - Liang et al () China Case series Level IV Quality: poor N = 74 Metastases from: CRC: 28 Inclusion None specified Exclusion MTA Ultrasound-Guided Microwave Coagulator-I Outcomes Survival, complications Statistical analyses 16 patients eligible for resection elected to have MTA 62.7
1402-%20Final%20Contracted%20Assessment%20Report%20(ACCESSIBLE).docx